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Is Microscopic Colitis a Drug-induced Disease?
Daniel Keszthelyi, MD,* John Penders, PhD,wz Ad A. Masclee, MD, PhD,*
and Marieke Pierik, MD, PhD*
Abstract: Microscopic colitis (MC) is diagnosed in up to 13% of
patients investigated for chronic diarrhea, particularly in middle-
aged and elderly patients. Recent studies have suggested an
etiological role for various drugs, including nonsteroidal anti-
inflammatory drugs and proton pump inhibitors. To ascertain the
potential role for drug exposure in the development of MC, we
performed a systematic review based on a MEDLINE search and
conducted a meta-analyses on the available data. We also give an
overview of the case reports and studies illustrating the role of
drugs in inducing MC. A number of hypotheses are formulated
with regard to the potential pathophysiological mechanisms in
drug-induced MC. However, confirmative evidence is still largely
lacking. Considering the high number of drug users and the rela-
tively low incidence of MC, it is more likely that drug-induced cases
of MC are the result of an idiosyncratic reaction.
Key Words: microscopic colitis, drug exposure, proton pump
inhibitors, NSAIDs, systematic review, collagenous colitis, lym-
phocytic colitis
(J Clin Gastroenterol 2012;46:811–822)
Microscopic colitis (MC) is an umbrella term for collag-enous colitis (CC) and lymphocytic colitis (LC). MC is
characterized by the combined presence of watery diarrhea, a
macroscopically normal ileocolonoscopy and typical micro-
scopic findings.1 The histologic changes of MC comprise an
increased number of intraepithelial CD8+ T lymphocytes,
exceeding 20 per 100 surface epithelial cells, accompanied by
superficial epithelial damage and a variable inflammatory
infiltrate in the lamina propria. In addition, in CC, a thickened
subepithelial collagen band, which exceeds 10mm, is present.
These histologic characteristics are not pathognomic as they
may occur in various inflammatory conditions in the colon.2
MC can be diagnosed in patients of any age, but pri-
marily affects the elderly. The average age of patients
diagnosed with LC or CC ranges from 53 to 69 years.3
Also, MC seems to be more frequent in women than in
men. In the past, MC was thought to be a rare disorder.
However, it has recently become apparent that MC is
diagnosed in up to 13% of patients investigated for chronic
diarrhea, particularly if middle-aged or elderly.2,4 Pardi
et al4 reported an increasing annual incidence rate up to 7.1
for CC and up to 12.6 for LC per 100,000 person-years in
the period of 1998 to 2001. Along the same line,
Scandinavian studies have also shown increasing incidences
for both LC and CC (Table 1).
It is apparent that the induction of inflammation in
the lamina propria is a key pathogenetic factor in MC. How-
ever, the exact mechanisms involved in the initiation and
development of MC remain to be elucidated and several
pathophysiological mechanisms have been proposed. Genetic
susceptibility was suggested because of reports of familial
clustering of the disease.10,11 Secondly, the reported seasonal
variation in incidence indicates an infectious cause.12 To date,
no causal enteropathogen has been identified and antibiotics
are not effective in the treatment of MC. Over 40% of the
patients with MC have coexisting autoimmune diseases such as
celiac disease or thyroiditis pointing to potential involvement of
autoimmune mechanisms.2,6,13 Furthermore, for CC, myofi-
broblast dysfunction has been described.14–16 Finally, noxious
luminal substances such as drugs and smoking may trigger the
chronic inflammation seen in MC and one postulated
hypothesis points to increased colonic permeability in MC
patients, thereby allowing luminal antigens to enter the lamina
propria and elicit an immune and inflammatory reaction.17
The increasing incidence of MC may partially be
explained by an increased awareness of the condition
among clinicians and histopathologists. Moreover, a vari-
ety of drugs has been associated with MC and has even
been suggested to induce MC. The increased use of medi-
cations especially in older people might explain the reported
increased incidence of MC.3 To shed more light with regard
to current evidence regarding the role of drug exposure in
MC and the mechanisms involved we performed a sys-
tematic review of the literature.
MATERIALS AND METHODS
Literature Search
We executed a MEDLINE search using the terms:
“microscopic colitis” or “lymphocytic colitis” or “collagenous
colitis.” The language restrictions were English, French,
TABLE 1. Incidence Rates (per 100,0000) of Collagenous Colitis
(CC) and Lymphocytic Colitis (LC)
Period
Investigated CC LC References
USA 1985-1997 1.6 2.7 Pardi et al4
1998-2001 7.1 12.6
Sweden 1984-1993 1.8 No
data
Bohr et al5
1993-1998 4.9 4.4 Olesen et al6
Iceland 1995-1998 5.2 4.0 Agnarsdottir et al7
Spain 1993-1997 2.3 3.7 Fernandez-Banares
et al8
Canada 2002-2004 4.6 5.4 Williams et al9
From the Departments of *Internal Medicine, Division of Gastro-
enterology-Hepatology; wEpidemiology; and zMedical Micro-
biology, Maastricht University Medical Center, Maastricht, The
Netherlands.
The authors declare that they have nothing to disclose.
Reprints: Daniel Keszthelyi, MD, Division of Gastroenterology-Hep-
atology, Department of Internal Medicine, Maastricht University
Medical Centre, PO Box 5800, 6202 AZMaastricht, The Netherlands
(e-mail: daniel.keszthelyi@maastrichtuniversity.nl).
Copyright r 2012 by Lippincott Williams & Wilkins
CLINICAL REVIEW
J Clin Gastroenterol  Volume 46, Number 10, November/December 2012 www.jcge.com | 811
German, or Dutch. The initial search resulted in 529 hits. The
abstract, or when available, the full paper was reviewed by 2
reviewers independently and papers were excluded if not
reporting on drugs and MC. For 13 hits, no abstract or paper
was available and were therefore excluded. After initial
review, 26 papers were found eligible for further review.
Review of the references of the included papers resulted in 2
additional case reports (see Fig. 1 for PRISMA flowchart).
Meta-analysis
Eventually, the meta-analysis was performed using
data from the only 3 case-control studies assessing exposure
to medication in MC.18–20 These 3 studies all reported on
nonsteroidal anti-inflammatory drugs (NSAIDs) and only 2
of them on proton pump inhibitors (PPIs). Therefore, only
data on NSAID exposure were considered for meta-anal-
ysis. Also, the patient populations examined were not
entirely homogenous, some examining CC and LC sepa-
rately, for instance. For this reason, in case of the study of
Fernandez-Banares et al,19 we pooled the drug exposure
rates from CC and LC cases before the meta-analysis.
For each of the included studies, odds ratios (ORs)
and their 95% confidence intervals were calculated based
upon the reported drug exposure rates in MC patients and
controls. To derive a pooled OR from individual studies, we
used a random-effects meta-analysis model. It is important
to note, that we were not able to correct ORs for age, sex,
and other confounders and therefore only report crude
ORs. Heterogeneity was quantified with the I2 index, which
describes the proportion of total variation in study esti-
mates due to heterogeneity.21
Statistical analyses were conducted using the “metan”
command within Stata version 11 (Stata Corp., College
Station, TX). The results are displayed in a forest plot.
RESULTS AND DISCUSSION
NSAIDs
Of all drug groups suggested to play an etiological role
in MC, the most convincing evidence exists for NSAIDs. A
summary of case reports of NSAID-induced MC is given
in Table 2. We also present a summary of cases reporting
on the association with the exposure to Cyclo 3 forte, a
venotonic drug used in France, also containing aspirin
(Table 3). It is, however, important to acknowledge that it
is unclear whether the association is related to aspirin or the
other components on Cyclo 3 forte.
In an early prospective study, NSAIDs were impli-
cated in 10% of newly diagnosed cases of colonic inflam-
mation, and patients taking NSAIDs had a 5-fold risk for
developing a colonic disease.29 In later years, a substantial
number of studies have reported on a positive association
with NSAID exposure and MC20,23,30–32 (see Table 4 for
cohort studies). This association seems more apparent with
CC.19 Numerous studies have reported high use of NSAIDs
among MC patients. In a retrospective review of 163
patients in Sweden with CC, 34% were taking NSAIDs on
a regular or sporadic basis.35 Another Scandinavian study
showed that 35% of the 104 patients with MC examined
used NSAIDs.36 In a case control study by Riddell, 31
patients with CC were compared with 31 controls with
irritable bowel syndrome or diverticulosis. Long-term use
of NSAIDs (for >6mo) was reported in 19 of 31 subjects
with MC, compared with only 4 of 31 controls. The case for
an etiological role for NSAID use and MC was strength-
ened by reports of clinical and histologic improvement
among NSAID users when the medication was dis-
continued.20,23–25 In the controlled study of 31 patients with
CC described previously, 3 subjects reported reduction in
diarrhea after they stopped taking NSAIDs. One subject,
who later resumed taking an NSAID, developed recurrent
diarrhea that resolved when the NSAID was again
discontinued.20
Given this apparent role for NSAIDs in MC, we
performed a meta-analyses based on the 3 case-control
studies published to date [pooled OR 3.25 (1.1-9.5),
see Fig. 2 for forest plot]. Although we did calculate the
pooled OR for NSAID exposure, it is important to note
that this should be interpreted with caution for the fol-
lowing reasons. First, the number of published studies
available for analysis is limited. Second, no correction was
possible for other confounders, since Riddell et al20 did not
present adjusted analyses, whereas we had to pool the drug
exposure rates of LC and CC for the study by Fernandez-
Banares et al19before meta-analyses. Third, the studies
report on different patients populations (MC pooled
together or LC and CC separately) as well as control
population (general population, patients controls or a
mixture of both). We therefore consider the findings of
these meta-analyses indicative rather than conclusive
regarding a possible etiological role for NSAIDs.
A potential confounding factor is the presence of
coexisting arthralgia in patients with MC, which could
increase their use of NSAIDs.37 A study reported that 18 of
31 (56%) patients with CC had some form of arthritis; and
71% of those were using NSAIDs regularly at the time of
diagnosis.9 Establishment of a cause-effect relationship here
is exceptionally challenging and cannot be performed on
the basis of the currently available datasets. Nevertheless,
several hypotheses can be postulated with regard to
potential pathophysiological mechanisms. Intestinal side
effects of NSAID have been documented extensively.
NSAIDs induce small intestinal and colonic injury and
inflammation and possibly may exacerbate IBD.32 Fur-
thermore, 60% to 70% of patients on long-term NSAID
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FIGURE 1. PRISMA flowchart for literature search.
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TABLE 4. Cohort Studies Assessing Medication Use in Microscopic Colitis
Study
Sveinsson et al33 Pardi et al34 Goff et al31 Bohr et al35









Inclusion period 1995-1999 1997-1999 Before 1992 1989-1995
MC 125 189 31 163
LC 71 176 — —
CC 54 6 31 163








MC 33% Aspirin 43.9% — —
Other NSAIDs 24.3%
Ticlopidine 3.7%*
LC 17% — — —

















*For 2 patients on ticlopidine dechallenge resulted in cessation of diarrhea.
CC indicates collagenous colitis; LC, lymphocytic colitis.
NOTE: Weights are from random effects analysis


















NSAID use and Microscopic Colitis
FIGURE 2. Forest plots for meta-analysis of nonsteroidal anti-inflammatory drug (NSAID) use in microscopic colitis. CI indicates con-
fidence interval.
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in fact been associated with increased risk for acute diar-
rhea.38 More recently, Gleeson and Davis39 reported that
74% of new cases presenting with colitis had been using
NSAIDs before the development of their disease.
Therefore, the alleged ability of NSAIDs to cause or at
least exacerbate MC is not altogether unexpected. NSAID-
related erosions and ulcers are most commonly seen in the
distal ileum and rectum. Small intestinal injury due to
NSAIDs differs pathophysiologically from that found in
the stomach, as prostaglandin suppression does not play an
important role.40 Rather, NSAIDs and bile have synergistic
effects with respect to injury of the small intestine by con-
tact irritation of the mucosa. The enterohepatic circulation
seems to be crucial in this regard, by allowing repeated
exposure to the offending chemicals. In the small intestine,
NSAIDs uncouple mitochondrial oxidative phosphor-
ylation leading to reduced intracellular ATP levels. This, in
turn, leads to loss of cytoskeletal control over tight junc-
tions and increased paracellular permeability.41 This
increased permeability may allow passage of certain, yet to
be identified luminal antigens, which can elicit a malicious
immune response, which, provided such mechanism is also
present in the colon, may potentially result in clinically
manifest MC.
PPIs
Recent studies have emphasized the association
between exposure to PPIs and occurrence of MC. Many
case reports have been published that further highlight the
association between PPI use and development of MC42–45
(Table 5). Initially, lansoprazole has been associated with a
high likelihood of inducing MC.50 In most published cases,
symptoms started within few weeks after start of lanso-
prazole therapy (median 21.5 d), and complete resolution
after lansoprazole discontinuation was observed within a
few days (median 7 d), without need for further therapy.51
Another recent study also pointed to similar effects in case
of exposure to omeprazole and esomeprazole.45 PPIs are
one of the most frequently prescribed classes of medications
worldwide because they combine a high level of efficacy
with low toxicity. In 2006, expenditure on these drugs was
10 billion USD globally.52 In the 5 years since the intro-
duction of esomeprazole in 2001, prescriptions for PPIs
have doubled.52 It is noteworthy, that the increasing inci-
dence of MC4 seems to parallel the rising use of PPIs.
Besides a number of case reports and case series, only
a very limited number of controlled studies have examined
the role of PPI exposure in MC,18,19 of which only one
found a positive association.18 More comprehensive studies
are still lacking for PPIs to support an etiological role for
PPIs in MC.
The potential pathophysiological mechanisms under-
lying PPI-related induction of MC are poorly understood.
When patients are prescribed PPIs to treat upper gastro-
intestinal disorders, it is important to recognize that PPIs
are interacting at multiple targets. Proton pumps (H+/K+
ATPases) are present not only on gastric epithelium but
also on colonic epithelium where they contribute to whole-
body potassium homeostasis.53 Inhibition of the colonic
proton pumps may therefore affect local electrolyte balance
and compromise fluid acidification, which can possibly
affect immune reactions in the colonic mucosa. Auto-
radiographic studies using 3H-lansoprazole in animal
models have shown uptake of the drug in the colonic
mucosa, both in upper colonic epithelial cells as well as in
inflammatory cells.54
Proteins other than H+/K+ ATPase have also been
reported as targets for PPIs. Omeprazole and lansoprazole
have been observed to induce smooth muscle relaxation and
to inhibit contractile activity.53 This effect on contractile
systems may also affect tight junction functionality as tight
junction proteins are directly linked to the actinomyosin
cytoskeleton. Therefore, conformational changes in the
cytoskeleton of epithelial cells may result in alterations in
the function of the tight junction, which leads to increased
paracellular permeability. As a result, luminal contents can
more easily penetrate the lamina propria causing an
immune and/or inflammatory reaction. Esomeprazole has
been shown to increase paracellular permeability in the
upper gastrointestinal tract in vitro55 and in vivo in
humans.56 Increased paracellular permeability has been
observed in MC and is considered a key component in the
induction of diarrhea.57 Accordingly, expression of the
tight junction proteins occludin, claudin-4, and zonula
occludens-1 was found to be decreased in mucosal biopsy
specimens fromMC patients.57,58 We speculate that a direct
or indirect effect of PPIs on colonic tight junctions and
paracellular permeability, similar to that of NSAIDs, may
be a potential mechanism in the development of MC.
Recent case reports have related the occurrence of
severe hypomagnesemia to long-time PPI exposure.59,60
This effect has been described for omeprazole, esomepra-
zole, pantoprazole, and lansoprazole.59 It has been pro-
posed that PPIs induce a defect in the active absorption of
magnesium in the intestine. This may result from an effect
of PPIs on the tight junction proteins or on the TRPM6 and
7 channels (transient receptor potential melastin 6 and 7).
The latter are key molecules involved in active magnesium
absorption. Either changes in intestinal pH induced by PPIs
may affect channel functions, or subjects who are hetero-
zygous carriers of TRPM6/7 mutations are more suscepti-
ble to developing adverse reactions to PPIs.60 Presently, we
cannot exclude that effects of PPIs on magnesium absorp-
tion have a role in the pathogenesis of MC. The fact that
distinct genetic profiles can be of superior importance
with regard to the development of side effects during
PPI therapy is further supported by reports describing
agranulocytosis and neutropenia induced by PPI.61 A
recent report demonstrated that this is caused by a muta-
tion of the CYP2C19*17, the enzyme responsible for PPI
metabolism.62
In addition, it is well known that PPI therapy affects
intestinal microbial profiles.63–66 Several bacteria, including
Helicobacter pylori and Streptococcus pneumoniae, as well
as fungi such as Candida albicans, contain H+/K+
ATPase in their plasma membranes that are highly
homologous to their human counterparts.67 PPIs can
therefore directly influence microbial growth by inhibition
of the H+/K+ ATPase. In contrast, increase of intestinal
pH can result in a diminished host defense against certain
bacteria. Profound acid suppression increases the risk of
enteric infections in susceptible individuals caused by Shi-
gella, Salmonella, Yersinia, or Clostridium difficile.68 The
use of PPIs may also promote the expansion and colo-
nization of C. difficile by its recognized potential to induce
small bowel bacterial overgrowth with anaerobic colonic
organisms.63 Many clinicians believe that PPI use may
therefore directly contribute to C. difficile and other bac-
terial infections. The FDA has in fact recently issued a
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safety announcement that PPI use may be associated with
C. difficile infection.69 A recent study by Lombardo et al70
also suggested that PPI therapy in humans may potentially
result in small intestinal bacterial overgrowth. Whether
these changes in intestinal microbiota induced by PPI
therapy are truly responsible for the development of
symptoms and clinical conditions remains subject to con-
siderable discussion.71 Further research is needed to clarify
the exact effects of PPIs on human intestinal microbiota.
Nevertheless, alterations in intestinal microbiota
should also be considered as a possible pathogenetic factor
in MC. The role of microbiota in regulating intestinal
function has increasingly been appreciated and perturba-
tion of intestinal microbiota seems plausible in MC.72 The
anatomic sites of highest bacterial concentration in the gut
(cecal and right colon) are the sites most frequently affected
by inflammation.30 There is also some, albeit not robust,
evidence that CC patients may benefit from treatment with
probiotics.73
Coexposure to NSAIDs and PPIs
PPIs and NSAIDs are often used simultaneously, with
the former frequently coprescribed to reduce gas-
trointestinal injury due to the latter. Recent video cap-
sule studies suggest74,75 a very high incidence (55% to 70%)
of intestinal damage in healthy humans taking both
NSAIDs and PPIs for 2 weeks. A more recent study per-
formed in rats demonstrates that PPIs induced a marked
exacerbation of small intestinal ulceration induced by
NSAIDs, which was transferable to germ-free mice through
microbiota isolated from the PPI-treated rats, suggesting an
important role for microbial alterations. When PPIs were
administered alone, significant changes in intestinal micro-
biota were observed, with 80% reduction in the levels of the
beneficial Bifidobacteria spp., whereas little morphological
effect was detected on the intestinal mucosa.76
Overall, it is tempting to assume that PPIs can
potentially induce alterations in intestinal microbiota, albeit
not to a clinically significant degree, which can in turn
impair the capacity of the intestine to respond to potentially
noxious agents, such as NSAIDs, known also to affect
intestinal barrier function. Such a “2-hit” theory could
provide an explanation for the relevance of coexposure to
PPIs and NSAIDs in the development of MC. Recent
results suggest a higher intake of PPIs with NSAIDs in
patients with MC compared with controls from the general
population.18 However, in the published case reports, only
2 of 20 patients were using PPIs and NSAIDs simulta-
neously. Further studies are warranted to provide con-
firmative evidence on this potential additive effect of
coingestion.
Other Drugs
A number of other drugs have been proposed to be
associated with MC (Table 6). Ticlopidine, for instance, has
also been reported in a number of cases to be the cause of
MC. The possible underlying mechanism was suggested to
be related to induction of apoptosis of epithelial cells in the
colonic crypts.83 Other drugs that have been associated with
the induction of MC include ranitidine,79 acarbose,84 the
venotonic drug Cyclo 3 forte, flutamide,30 b-blockers,19 and
statins.85 The association of statins with colitis has been
based on an ischemic pathophysiology.86
CONCLUSIONS
Diarrhea is a frequent adverse event induced by drugs,
accounting for about 7% of all adverse effects of drug
therapy and over 700 drugs have been claimed to cause
diarrhea.87 Drugs or their metabolites may cause diarrhea
directly through their pharmacological properties or
through idiosyncratic hypersensitivity reactions. Fur-
thermore, drugs can alter the colonic microbiota and sub-
sequently cause diarrhea.
The concept that some drugs may cause or worsen MC
was first proposed in the 1990s.20,23 Olesen et al88 estimated
10% of all MC cases to be induced by drugs. The low
frequency of MC associated with drugs of different phar-
macodynamic profile, on the other hand, favors the path-
ophysiological mechanism to be of idiosyncratic nature.
Resolution of symptoms after discontinuation of a drug
and recurrence of diarrhea after rechallenge is a strong
argument for such an idiosyncratic drug reaction. In a
recent literature review, Beaugerie and Pardi50 suggested
the use of a scoring system to determine the strength of
evidence that associated individual drugs or drug classes
with MC. NSAIDs, aspirin, PPIs, ranitidine, selective
serotonin reuptake inhibitors, ticlopidine, acarbose, and
statins had high or intermediate levels of association with
the disease. Carbamazepine, flutamide, and paroxetine had
less well-established associations with MC. A more recent
study indeed confirmed a role for NSAIDs, selective sero-
tonin reuptake inhibitors, statins, and PPIs, but also
bisphosphonates and b-blockers.19 Reports have also pro-
posed that aspirin, sertraline, simvastatin, and lanzoprazole
may be more likely to be associated with MC than other
medications in the corresponding classes.19,50
In principle, the causative role of a certain drug can be
proven by demonstrating that (a) intake of the drug pre-
cedes the manifestation of disease, (b) discontinuation of a
certain drug results in symptom resolution (dechallenge),
(c) recurrence of the disease when medication is resumed
(rechallenge), and (d) other causes of disease have been
excluded. However, for most drugs having been associated
with MC, rechallenge has not been performed or reported
and the number of cases is small, such that an association
by chance cannot be ruled out. Apart from case reports, the
very limited number of retrospective studies assessing
medication use and presence of disease generally do not
allow to establish a cause-effect relationship as such studies
are largely confounded by other factors, such as comorbid
conditions, for which the use of certain pharmacological
therapy is indicated. Furthermore, depending on the
methods used for data acquisition, recall bias can largely
influence drug exposure rates. Performing such studies
aimed at defining certain associations in MC is challenging
considering the higher age of patients affected and thereby
frequent medication use. Such approaches should, however,
be able to shed light on a positive association between the
use of certain drugs and the disease condition. This enables
the formulation of working hypotheses, provided that
biological plausibility to ascertain a legitimate causative
role of a drug is present.
Several factors can be found to explain a positive asso-
ciation with drug exposure and MC, apart from a cause-and-
effect relationship. First, as for NSAIDs, many drugs that are
associated with MC, including PPIs, induce watery diarrhea
as common adverse effect. Thus, by causing or worsening
diarrhea, use of these drugs can result in identification of MC,
rather than being the primary etiological factor.
Keszthelyi et al J Clin Gastroenterol  Volume 46, Number 10, November/December 2012
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Second, one should consider that greater awareness of
physicians and subsequent increase in exposure to colono-
scopy with biopsy among patients receiving these medi-
cations may merely lead to an apparent increase in the
diagnosis of MC.
Third, the growing list of distinct drugs and drug
classes potentially associated with MC, and largely variable
time interval between start of drug use and onset of MC
symptoms, indicate the great difficulty in establishing an
association between specific agents and MC.35 Never-
theless, because of the associations between MC and
NSAIDs, PPIs, and other medications, in individual cases,
drug use and recent history should be carefully reviewed in
patients with watery diarrhea or newly diagnosed MC.
Agents that cause symptoms might be identified based on
the temporal relationship between the timing of drug use
and onset of symptoms.
The fact that most case reports of drug-induced MC
concern suspected adverse drug reactions remains an
inherent problem in pharmacovigilance. Adverse reactions
are rarely specific for the drug and a rechallenge, which can
add suggestive evidence for a causative role, is rarely ethi-
cally justified. In an attempt to solve this problem, many
systems have been developed for a structured and
harmonized assessment of causality, the most commonly
used being the WHO-Uppsala Monitoring Center89 and the
Naranjo criteria.90 None of these systems, however, have
been shown to produce a precise and reliable quantitative
estimation of relationship likelihood resulting in a lack of
international consensus regarding causality assessment.
Nevertheless, valid arguments for causality have been
provided by studies showing marked improvement in
symptoms or histology after stopping the drug and in some
cases rechallenge resulting in symptom relapse. Overall,
evidence exists to support the role of certain drugs, in
particular NSAIDs and PPIs, are able to contribute to the
development of MC. In terms of disease development, it is
tempting to assume that MC induced by a heterogeneous
group of drugs possibly shares a common multistep
pathophysiology related to the impairment of the intestinal
epithelial barrier. Drug-induced impairment of the barrier
may set the stage for further, as yet undetermined, insults
through a luminal antigen that precipitates the disease. By
virtue of interfering with intestinal homeostasis, they may
potentially initiate or exacerbate ongoing unfavorable
mucosal immune activation resulting in clinically manifest
MC. Even though accumulating evidence suggests a role for
certain drugs in disease development, it is obviously not the
sole factor in MC.
In conclusion, we systematically reviewed the literature
on medication use and MC. In individual cases, drugs such
as NSAIDs and PPIs should be considered as potential
etiological factors. Patients taking these drugs may therefore
warrant investigation for MC when developing watery
diarrhea. It is crucial to ascertain the temporal relationship
between exposure and symptom onset to support a causative
role. After diagnosis, attempt should be made to discontinue
the suspected drug. Although a number of hypotheses have
been formulated with regard to potential pathophysiological
mechanisms in drug-induced MC, confirmative evidence
is still largely lacking. Given the wide use of these drugs
among the general population and the relative rarity of the
condition, drug-induced MC seems to be an uncommon
complication, which most probably simply reflects an un-
fortunate idiosyncratic reaction to the particular drug.
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